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Abstract
Background: Cisplatin is a potent anticancer drug, but its clinical application has been limited due to its undesirable
physicochemical characteristics and severe side effects. Better drug formulations for cisplatin are highly desired.
Methodology/Principal Findings: Herein, we have developed a nanoparticle formulation for cisplatin with high
encapsulation efficiency and reduced toxicity by using cisplatin-crosslinked carboxymethyl cellulose (CMC) core
nanoparticles made from poly(lactide-co-glycolide)-monomethoxy-poly(polyethylene glycol) copolymers (PLGA-mPEG).
The nanoparticles have an average diameter of approximately 80 nm measured by transmission electron microscope (TEM).
The encapsulation efficiency of cisplatin in the nanoparticles is up to 72%. Meanwhile, we have also observed a controlled
release of cisplatin in a sustained manner and dose-dependent treatment efficacy of cisplatin-loaded nanoparticles against
IGROV1-CP cells. Moreover, the median lethal dose (LD50) of the cisplatin-loaded nanoparticles was more than 100 mg/kg
by intravenous administration, which was much higher than that of free cisplatin.
Conclusion: This developed cisplatin-loaded nanoparticle is a promising formulation for the delivery of cisplatin, which will
be an effective therapeutic regimen of ovarian cancer without severe side effects and cumulative toxicity.
Citation: Cheng L, Jin C, Lv W, Ding Q, Han X (2011) Developing a Highly Stable PLGA-mPEG Nanoparticle Loaded with Cisplatin for Chemotherapy of Ovarian
Cancer. PLoS ONE 6(9): e25433. doi:10.1371/journal.pone.0025433
Editor: Martin W. Brechbiel, National Institutes of Health, United States of America
Received April 28, 2011; Accepted September 5, 2011; Published September 26, 2011
Copyright:  2011 Cheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge support from the China International Science and Technology Cooperation Foundation (2007DFC30306, http://www.cistc.
gov.cn/), and the Zhejiang Province Technology Project Foundation (2009C11122, http://www.zjkjt.gov.cn/html/index.htm). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: chenglihua75@gmail.com
Introduction
Cisplatin-based therapeutic regimens have been established as
the standard first-line chemotherapy for patients with ovarian
cancer since the mid-1980s [1–3]. However, its application has
been limited because of severe side effects and cumulative toxicity
on major organs such as liver, kidney, heart and nervous system by
intravenous administration [4–7]. In recent years, numerous nano-
sized drug carriers have been developed to minimize side effects of
cisplatin and enhance its antitumor efficacy through the forms of
micelles such as poly(aspartic acid)-poly(ethylene glycol) micelles,
liposomes such as pegylated liposomes and solid lipid nanoparticles
during cancer therapy [8–13]. Soluble drug-polymer conjugates
have also been developed to increase the solubility of cisplatin.
Such conjugates include cisplatin complexes with polycarboxy-
lates, poly(amidoamines), polyamidoamine dendrimers and poly-
acrylic chains. These systems can reduce toxicity and achieve ideal
efficacy of chemotherapy [14–16].
Poly(lactic-co-glycolic) acid (PLGA) microparticles have also
been used for cisplatin entrapment due to its biocompatible and
biodegradable properties [17,18]. Avgoustakis K et al. have
demonstrated that the intravenous administration of PLGA-
mPEG nanoparticles loaded with cisplatin results in a significant
prolongation of cisplatin presence in blood of mice [19]. However,
the encapsulation efficiency of cisplatin is still poor during the
preparation of PLGA-mPEG nanoparticles loaded with cisplatin.
Gryparis EC et al. [20] have found that nanoparticle application
has the possibility to maintain adequate or more concentrations of
cisplatin for 2 weeks, but relatively low PEG content of PLGA-
mPEG can induce the increase of nanoparticle size. Furthermore,
it is desirable to achieve a sustainable release and sufficient
concentration of cisplatin in clinical settings because continuous
low-dose administration of cisplatin is more effective in inducing
apoptosis than a single high-dose exposure of cisplatin [21,22].
The main objective of the present work is to develop an
innovative nanoparticle with a high encapsulation efficiency and
sustainable release of cisplatin. In this nanoparticle delivery
system, d-alpha tocopheryl polyethylene glycol 1000 succinate
(TPGS) as a new efficient emulsifier beneficial for human health
has been used and the biodegradable PLGA-mPEG nanoparticles
with CMC cores have been developed. Meanwhile, the loading
and encapsulation efficiency of cisplatin have also been deter-
mined. Moreover, the antitumor efficacy of nanoparticles loaded
with cisplatin on mouse ovarian cancer model has been evaluated.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25433In conclusion, the improved cisplatin delivery system provides a
rational design for potential therapeutic application of cisplatin in
ovarian cancer.
Results
Rational design of CMC and TPGS to prepare PLGA-mPEG
nanoparticles with cisplatin
It is a challenge to prepare nanoparticles loaded with cisplatin
by using PLGA-mPEG copolymers due to their physicochemical
properties and preparation conditions. In this study, we conducted
a rational design of nanoparticles containing cisplatin by tailoring
the compositions, size and shape. Firstly, PLGA-mPEG copoly-
mers were synthesized from lactide and glycolide in the presence
of mPEG5000, whose hydroxyl group could initiate the ring-
opening polymerization of lactide and glycolide. The structure of
the synthesized copolymer was detected by
1H NMR in CDCl3,a s
shown in Figure 1. The peaks at 1.65 and 5.10 ppm belonged to
the protons from methine (-CH) and methyl (-CH3) groups of
PLGA segments, while the peaks of methene protons (-CH2-) in
the PEG segments located at 3.65 ppm, and the peaks of methene
protons (-COCH2O-) located at 4.78 ppm were the representation
of conjugated segments of PLGA and mPEG so that no other
peaks were detected. The only one peak in GPC spectrum
(Figure 2) revealed the successful synthesis of PLGA-mPEG
copolymers with high purity. The polydispersity index (PI) as a
measurement of the distribution width for molecular weights was
1.78. On the basis of gel permeation chromatography (GPC) and
the ratio of
1H peak areas between 5.10 and 3.65 ppm, the
average molecular weight of synthesized copolymers was calculat-
ed to be 37062, as shown in Figure 2. The weight percentage of
mPEG was 13.5%.
Secondly, a modified solvent evaporation method based on
water-organic phase-water (W/O/W) multiple emulsions includ-
ing a relatively simple preparation process was used to improve the
encapsulation efficiency of cisplatin in nanoparticles. The observed
characteristics of nanoparticles may vary largely depending on
CMC concentration, TPGS concentration and the variable
processes including the switch of solvent addition order. In order
to achieve the optimal CMC concentration for high encapsulation
efficiency, different addition amounts of CMC in the internal
aqueous phase of the double emulsion system were explored. The
effective encapsulation of cisplatin in nanoparticles was higher
than no amount of CMC, which revealed the loading rate and
encapsulation efficiency of cisplatin were 3.88 and 70.9% (w/w),
respectively, as shown in Table 1. Totally 1.7 mg CMC combined
with 4 mg cisplatin were selected as the optimal internal aqueous
phase and the optimal concentration for TPGS was screened to be
0.035% (w/v).
As shown in Table 2, the average size of prepared
nanoparticles loaded with cisplatin ranged from 180 to 210 nm,
and the loading rate of cisplatin was 3.5–4.2% (w/w). The PI was
determined to be approximately 0.3, which exhibited a
homogeneous distribution in diameter. CMC and PLGA-mPEG
polymers conferred a negative f-potential with an average value
of 210.1 and 29.5 mV in blank nanoparticles and cisplatin-
Figure 1.
1H NMR spectrum of PLGA-mPEG copolymer. The peaks at 1.65 and 5.10 ppm belonged to the protons from methine (-CH) and
methyl (-CH3) groups of PLGA segments, the peaks of methene protons (-CH2-) in the PEG segments located at 3.65 ppm, and the peaks of methene
protons (-COCH2O-) located at 4.78 ppm represented conjugated segments of PLGA and mPEG.
doi:10.1371/journal.pone.0025433.g001
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observed in size and f-potential of the nanoparticles with or
without cisplatin. Figure 3 showed the representative images of
the external structure of nanoparticles examined by TEM. Most
nanoparticles were spherical shape with smaller diameters than
the diameters determined by dynamic light scattering. The
morphology of nanoparticles with or without cisplatin revealed
indistinguishable or similar structures.
Lastly, the cumulative release profile of cisplatin from
nanoparticles was measured by high performance liquid chroma-
tography (HPLC), as shown in Figure 4. This assay method was
sensitive enough to measure cisplatin in a wide concentration
range with a detection limit of 0.31 ng/mL. A calibration curve
was established in each experiment. The release kinetics of
cisplatin from nanoparticles revealed a constant controlled release
rate as the function of time. However, its stable release could be
affected by CMC-cisplatin conjugation and biodegradable PLGA-
mPEG copolymers. Similarly, as shown in Figure 4, the
entrapment of cisplatin in nanoparticles could significantly retard
the release rate of cisplatin and consequently lead to a fairly steady
release over time.
Acute toxicity of CMC core nanoparticles
In order to evaluate the cytotoxicity of nanoparticles without
loading of drugs, the cytotoxicity of nanoparticles at the doses of
0.005, 0.02, 0.04 and 0.08 mg/mL were tested by using 96-well
microplates seeded with cells at a density of 3000 cells/well. The
cell growth curves of the control and nanoparticle-treated groups
were similar, suggesting that the nanoparticles at the tested
concentrations did not exhibit obvious toxicity on cells, as shown
in Figure 5(A). In addition, the maximum amount of nanoparticles
(0.08 mg/mL) and the density of 3000 cells/well were also the
optimal conditions for evaluating the effect of cisplatin-loaded
nanoparticles on cell growth in vitro.
The anticancer activity of free cisplatin and cisplatin-loaded
nanoparticles on IGROV1-CP cells in vitro was determined. As
shown in Figure 5(B), no significant difference in cytotoxicity
between cisplatin-loaded nanoparticles and free cisplatin at the
tested concentrations was observed (p.0.05). The cytotoxicty of
both free cisplatin and cisplatin-loaded nanoparticles was dose-
dependent. Therefore, PLGA-mPEG nanoparticles can contribute
to controlled release rate of cisplatin while preserving the
anticancer effectiveness of cisplatin.
In order to assess for potential toxicity risks, ICR mice were
intravenously injected with cisplatin-loaded nanoparticles at
Figure 2. The measurement of PLGA-mPEG copolymer molecular weight by GPC. The peak represented the average molecular weight of
synthesized copolymers was calculated to be 37062.
doi:10.1371/journal.pone.0025433.g002
Table 1. Entrapment efficiency and drug loading of NPs-cp
(n=3).
Batch Entrapment efficiency Drug loading
NPs-cp 70.962.6% 3.960.3%
The entrapment efficiency was calculated as the amount of cisplatin recovered
from nanoparticles relative to the initial amount of cisplatin used for
preparation. The loading efficiency of cisplatin was the amount of cisplatin
recovered from nanoparticles relative to the amount of CMC and PLGA-mPEG.
doi:10.1371/journal.pone.0025433.t001
Table 2. Particle size and zeta potential of blank NPs and
NPs-cp (n=3).
Batch
Particle
size (nm)
Size polydis-
persity index (PI)
Zeta potential
(mV)
Blank NPs 18767 0.23 210.160.3
NPs-cp 192612 0.26 29.560.4
NPs are nanoparticles; NPs-cp is cisplatin-encapsulated nanoparticles.
doi:10.1371/journal.pone.0025433.t002
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examined. In all tested dose levels, death rates between groups
revealed a significant difference during a 2-week waiting period
(p,0.05). The mortality of cisplatin-loaded nanoparticles at the
dose of 100 mg/kg (on the basis of cisplatin) was 40.0%, but the
death rate in the 10 mg/kg cisplatin treatment group reached up
to 62.5%. No health deterioration was observed in mice treated
with blank nanoparticles during the observation period, and the
overall behavior of the mice treated with cisplatin-loaded
nanoparticles or blank nanoparticles did not exhibit an obvious
difference. The LD50 was 8.6 mg/kg for free cisplatin and
103.4 mg/kg for cisplatin-loaded nanoparticles, as shown in
Table 3. Therefore, compared with free cisplatin, the nanopar-
ticles loaded with cisplatin can provide more safety in clinical
application.
Safety profile of CMC core nanoparticles in IGROV1-CP
xenografted nude mice
In order to observe the delayed organ toxicity on the mice
within a certain treatment period, major organs including heart,
liver, lung, kidney and spleen from BALB/c nude mice
administered with free cisplatin and cisplatin-loaded nanoparticles
were sectioned and stained with HE. No obvious histopathological
change was observed in heart, lung and spleen of cisplatin-loaded
nanoparticles treated mice, as shown in Figure 6. However,
hepatic necrosis and pathological atrophy of kidney in mice
treated with free cisplatin were observed. Similarly, the adminis-
tration of cisplatin-loaded nanoparticles up to 3 mg/kg for 5
consecutive dosages did not cause a significant pathological
difference in liver and kidney.
In order to evaluate the effect of cisplatin-loaded nanoparticles
on apoptosis, tumor tissue sections were stained with TUNEL for
evaluating DNA fragmentation. Enumeration of apoptotic nuclei
(about 200 cells were counted) was made on slides picked up at
random by two independent experimenters. A cluster of apoptotic
bodies were given as a single count, and apoptotic counts in
different treatment groups were shown in Figure 7(A). Xenografts
treated with cisplatin-loaded nanoparticles revealed higher
apoptotic levels than the controls (saline and blank nanoparticles,
p,0.05). Although total counts of apoptotic cells in tumors treated
with cisplatin-loaded nanoparticles were slightly higher than those
in tumors treated with conventional cisplatin, no significant
difference in total counts of apoptotic cells in both treatment
groups was observed, as shown in Figure 7(B) (p.0.05).
Treatment efficacy in vivo studies
The treatment efficacy of cisplatin-loaded nanoparticles for
IGROV1-CP cell xenograft in BALB/c nude mice was evaluated.
After the average volume of the tumors was up to 100–130 mm
3,
the tumor-bearing mice were divided into four groups (n=8) with
minimal difference in weight and size of tumors among groups. In
addition, the mice were treated with following regimens including
saline, nanoparticles without cisplatin, free cisplatin, and cisplatin-
loaded nanoparticles every four days. The dose of cisplatin-based
treatments was 3 mg/kg body weight.
Tumor size, body weight and survival rate of the mice were then
monitored for 21 days following the beginning of treatment. The
mean tumor volume at the end of the treatment period was
209625 mm
3 in saline-treated group, and 213619 mm
3 in blank
nanoparticle-treated group, as shown in Figure 8(A). However, in
cisplatin-treated group, the final mean tumor volume was
166616 mm
3, which was significantly smaller than that in
saline-treated groups by ANOVA analysis at 95% confidence
interval. Compared with the cisplatin-treated group, a slight
reduction of tumor volume in cisplatin-loaded nanoparticles
treated group with mean tumor size of 146619 mm
3 at end of
treatment period. One possible reason was that the subsequent
intracellular delivery of cisplatin may be hindered by mPEG
modification of nanoparticles, which did not exhibit a significant
contribution on tumor reduction. At the end of treatment period
(days 21), the survival rates of the mice in the cisplatin-loaded
nanoparticles-treated group, cisplatin-treated group, blank nano-
Figure 3. Transmission electron microscopic examination of nanoparticles. (A) blank nanoparticles; (B) cisplatin-loaded nanoparticles.
Samples were stained with 1% phosphotungstic acid (500006).
doi:10.1371/journal.pone.0025433.g003
Figure 4. Release profiles of cisplatin-loaded nanoparticles.
Cisplatin released from nanoparticles as a function of incubation time in
100 mmol/L sodium chloride solution at 37uC.
doi:10.1371/journal.pone.0025433.g004
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and 75%, respectively, as shown in Figure 8(B). The difference in
survival rates from four groups suggested that cisplatin-loaded
nanoparticles were much safer than free cisplatin. The body
weights of the mice exhibited a gradual decrease starting from the
second dose although no significant difference in four groups was
observed, as shown in Figure 8(C).
Discussion
Physicochemical characteristics of cisplatin, such as poor
solubility in water (1 mg/mL), high binding affinity to plasma
proteins and degradability, may limit the therapeutic efficacy of
cisplatin. Cisplatin-based obstacles on its clinical application can
be resolved by using bioavailable polymeric nanoparticles.
Currently, some types of nanoparticles prepared from poly(lac-
tide)-monomethoxy-poly(ethyleneglycol) (PLA-mPEG) and PLGA-
mPEG copolymers have gained increasing attention. The
rationale of this study is to increase the loading and encapsulation
efficiency of cisplatin by nanoparticles, thus improving the stability
of cisplatin. TPGS also can provide a safe alternative of polyvinyl
alcohol (PVA) or other additives for improving the preparation of
uniform nanoparticles from batch to batch.
Using modified W/O/W double emulsion method developed
by Gryparis EC et al. [20], we have developed a novel concept of
‘‘core-CMC-cisplatin-crosslinking’’ that can greatly enhance the
loading efficiency of cisplatin. During the crosslinking of CMC,
chloride ion in cisplatin can exchange hydrogen ions with CMC in
water to form a complex. Due to the retention of the complex in
the primary emulsion phase, cisplatin can be loaded into the
nanoparticles made of hydrophobic PLGA with hydrophilic
methoxy polyethylene glycol chains. The loading efficiency of
cisplatin has improved to 3.960.3% (w/w), and the encapsulation
efficiency is up to 70.962.6%. Furthermore, there are no reports
related to the application of CMC polymers as a strategy to
improve the loading efficiency of cisplatin. Therefore, cisplatin-
loaded nanoparticles should be the effective drug delivery carriers
for cisplatin in vivo study.
The high encapsulation efficiency of cisplatin is also partly due
to the application of TPGS emulsifier in coordination-induced
nanoparticle formation. TPGS is different from previously
reported PVA, sodium cholate or other emulsifiers [17,20]. TPGS,
a water-soluble derivative of natural vitamin E, is commonly used
in pharmaceutical and nutraceutical formulations. In this study,
we have successfully generated homogeneous nanoparticles with
the aid of TPGS. No debris and aggregation in the homogenous
nanoparticles were observed by TEM. Monodisperse emulsion
droplets favors coalescence without TPGS, and the nanoparticles
are difficult to form. Here, TPGS is used with a hope to displace
above mentioned emulsifiers and avoid their removal trouble.
During the evaluation of cell viability and treatment efficacy of
prepared cisplatin-loaded nanoparticles, the viability of IGROV1-
CP cells incubated with free cisplatin at the concentration range of
8–24 mM for three days exhibited a decrease from 79.6% to
14.8%, while the viability of the cells treated with cisplatin-
encapsulated nanoparticles revealed a reduction from 76.9% to
10.8%. Moreover, the cisplatin-loaded nanoparticles effectively
inhibited the tumor growth in nude mice when compared with
free cisplatin at the same dose, suggesting that the nanoparticles
did not interrupt anticancer effectiveness of cisplatin in vivo.
TUNEL assay also confirmed the enhanced effectiveness of
cisplatin-loaded nanoparticles on tumor inhibition. Meanwhile,
histopathological examination revealed hepatic necrosis and
atrophy in kidney in the group treated with free cisplatin, but
these kinds of histopathological changes were not observed in the
groups treated with cisplatin-loaded nanoparticles. In addition,
other major organs such as heart, spleen and lung did not reveal
abnormalities either. Thus, the core-CMC-cisplatin-crosslinked
nanoparticles should be much safer and higher effectiveness than
free cisplatin during cancer treatment.
In order to further understand the side effects of cisplatin-loaded
nanoparticles, potential acute toxicity of cisplatin-loaded nano-
particles was also evaluated. ICR mice were intravenously injected
with 0.8 mL of cisplatin-loaded nanoparticles at the cisplatin
concentrations of 1.0, 1.5, 2.0, 2.5 and 3.0 mg/mL, respectively,
and the survival rate of the mice was examined. As expected, the
LD50 of cisplatin-loaded nanoparticles revealed 12-fold higher
than that of free cisplatin. Comparing the overall survival rate,
BALB/c mice showed more tolerance to cisplatin-loaded nano-
particles than free cisplatin, which indicated that cisplatin-loaded
Figure 5. Relative cell viability of IGROV1-CP cells with different treatments. (A) Relative cell viability of IGROV1-CP cells exposed to blank
nanoparticles for 72 hours with various doses. (B) Cell growth inhibition after exposure to free cisplatin (gray histogram) and cisplatin-loaded
nanoparticles (black histogram) for 72 hours. The data represented as Mean 6 SD.
doi:10.1371/journal.pone.0025433.g005
Table 3. LD50 of cisplatin and NPs-cp.
Tested nanoparticles LD50 (mg/kg)
Male Female Male+Female
NPs-cp 101.3 105.6 103.4
cisplatin 8.2 8.6 8.5
Each group included ten mice; LD50 represented as median lethal dose.
doi:10.1371/journal.pone.0025433.t003
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of relatively high administration dose.
In general, cisplatin-loaded nanoparticles have been successfully
designed and prepared. Spherical particles and narrow size
distribution have been characterized. Sustained release of cisplatin
over five days from PLGA-mPEG nanoparticles in vitro was
observed. Therefore, we can conclude that nanoparticles have a
significant contribution to the controlled release of cisplatin and do
not damage the treatment effectiveness of cisplatin. Our findings
provide further evaluation of cisplatin-loaded nanoparticles as a
novel cancer therapy. However, in order to maximize the
antitumor effect of cisplatin-loaded nanoparticles, it is necessary
to further optimize the administration dose and injection regime.
Current strategies, especially for making such nanoparticles,
involved multi-step preparation. As a result, the procedure is an
inherently inefficient system, which may not be easily scalable and
may result in batch-to-batch variation. In our laboratory, we have
developed a new method for the preparation of nanoparticles with
batch-to-batch uniformity. It is a simple, scalable, efficient and
controllable system using our well-designed formulation strategy.
Figure 6. Microscopic examination of organs with HE staining. Nude athymic mice bearing IGROV1-CP xenografts were treated with saline
(control), blank nanoparticles (blank NPs), cisplatin and cisplatin loaded nanoparticles (NPs-cp) at five doses every 4 days. The organs including heart,
lung, spleen, liver and kidney from the mice treated with saline were shown in the first row. The organs from the mice treated with blank
nanoparticles were shown in the second row. The organs from the mice treated with free cisplatin were shown in the third row. The organs from the
mice treated with cisplatin-loaded nanoparticles were shown in the fourth row.
doi:10.1371/journal.pone.0025433.g006
Figure 7. Apoptosis in tumor examined by TUNEL staining. (A) Microscopic evaluation of tumor apoptosis by TUNEL staining. Athymic mice
bearing IGROV1-CP xenografts were treated with saline (control), blank nanoparticles (blank NPs), cisplatin and cisplatin loaded nanoparticles (NPs-
cp) at five doses. (B) The average apoptotic cell counts were calculated on the basis of TUNEL staining. Athymic mice bearing IGROV1-CP xenografts
were treated as described in (A).
doi:10.1371/journal.pone.0025433.g007
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PLGA-mPEG nanoparticle formulation is a potential cisplatin
delivery system for ovarian cancer treatment.
Materials and Methods
Materials
Cisplatin was purchased from Shandong Boyuan Chemical
Co. Ltd. (Jinan, China). CMC was purchased from Aladdin
Reagent Co. Ltd. (Shanghai, China). mPEG (MW 5 kDa) and
TPGS were obtained from Jiangsu XiXin Vitamin Co. Ltd. The
reverse-phase column (ZORBAX-NH2,2 5 0 64.6 mm, 5 mm) was
purchased from Agilent Technologies Co. Ltd. (USA). All reagent
water used in the laboratory was pretreated with the Milli-Q Plus
System (Millipore Corporation, USA). All mPEG samples were
dehydrated by azeotropic distillation with toluene, and then
vacuum dried at 50uC for 12 h before use. IGROV1-CP cells
were kindly provided by Dr. Stephen Collins at UCSD (CA,
USA).
Animals
All animal experiments were conducted with the approval of
the Institutional Animal Ethics Committee (IACE) of the
Research Center of Laboratory Animal Science of Zhejiang
Chinese Medical University (Hangzhou, China). The permit
numbers are Syxk (zhe) 2008-0115. ICR mice and BALB/c mice
(4–6 weeks old and weighing 18–22 g) were kept at the animal
center. Cisplatin-loaded nanoparticles were administered with
intravenous injection. At the end of treatment periods, liver,
kidney, heart, spleen and lung tissues were collected as per the
approval of the IAEC.
Synthesis and characterization of PLGA-mPEG copolymer
PLGA-mPEG copolymers were prepared by a melt polymer-
ization process under vacuum using stannous-2-ethylhexanoate as
catalyst [23]. The PLGA(30)-mPEG(5) was synthesized with
composition LA:GA:EO=3:1:1, Mw (the weight average molec-
ular weight)=3.7610
4, PI=1.8 (LA, GA and EO stand for lactic
acid, glycolic acid and ethylene oxide components respectively).
The copolymer was characterized with
1H-NMR and GPC.
Preparation and characterization of cisplatin-loaded
nanoparticles
PLGA-mPEG nanoparticles loaded with cisplatin were prepared
with W/O/W emulsion solvent evaporation method developed by
Gryparis EC [20], with specific modifications. Briefly, 5.71 mg/mL
cisplatin dissolved in 30 mM CMC aqueous solution was emulsified
inanorganicphasebyusingsonication(bioruptor,modelUCD-200
TM-EX) at 100 W for 45 seconds. The organic phase was mainly
composed of chloroform and acetone containing 50 mg PLGA-
mPEG. Water-in-organic phase emulsion was added to an aqueous
solution of TPGS (0.035%, w/v).
The resultant W/O/W emulsion was then microfludized with a
minimum pressure of 12000 PSI, and agitated by a magnetic
stirrer for 3 h at room temperature until complete evaporation of
chloroform and acetone. Finally, the nanoparticle suspension was
lyophilized and stored at 4uC until future use. In order to increase
the entrapment of cisplatin in nanoparticles, CMC in the internal
aqueous phase of W/O/W was conjugated to cisplatin in 1 mL of
water for 3 hours with continuous gentle agitation. Blank
nanoparticles were also prepared with the same method without
cisplatin.
Particle size and zeta potential were measured by using Malvern
Zetasizer instrument (13 runs per sample, NETASIZER NANO
S90). The morphological examination of nanoparticles was
observed under TEM (JEM-1230, JEOL, Japan). One drop of
nanoparticle suspension was placed on a copper grid covered with
nitrocellulose membrane and dried in the open air before negative
staining with phosphotungstic sodium solution (1% w/v).
Determination of loading efficiency and in vitro release
rate of cisplatin
The loading efficiency of cisplatin in nanoparticles was
determined by using a direct procedure [24]. Totally 5 mg of
lyophilized nanoparticles was dissolved in 1 mL of NaOH (0.1 N)
and agitated overnight on a magnetic stirrer at room temperature.
The suspension was centrifuged at 18,000 g for 10 min, and 90 mL
of supernatant was used to quantify cisplatin content by HPLC.
The encapsulation efficiency was calculated as the amount of
cisplatin recovered from nanoparticles relative to the initial
amount of cisplatin used for each preparation. In addition, in
Figure 8. Effect of cisplatin-loaded nanoparticles on athymic mice. (A) Effect of free cisplatin (3 mg/kg) and cisplatin-loaded nanoparticles
(NPs-cp, 3 mg/kg on the basis of cisplatin) on tumor growth in athymic mice bearing with IGROV1-CP cell xenografts. The mice were administered
with prepared formulations at 4-day intervals in the total treatment period of 21 days. Saline solution was used as the control group, and the effect of
blank nanoparticles (blank NPs) was also confirmed. The data were presented as Mean 6 SD (n=8 at the beginning of the experiment). (B) Survival
rate of tumor-bearing athymic mice treated with cisplatin (3 mg/kg), NPs-cp (3 mg/kg on the basis of cisplatin), blank NPs and saline (control). (C)
Body weight change as the treatment time of IGROV1-CP tumor-bearing mice. Bars indicated standard deviations.
doi:10.1371/journal.pone.0025433.g008
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ticles, cisplatin-loaded nanoparticles (5 mg) were suspended in
10 mL of phosphate buffered saline (PBS). The suspension was
placed into a microcentrifuge tube and then put in an orbital water
bath shaking at 120 rpm at 37uC. The tubes were centrifuged at
designated time intervals. After centrifugation, the supernatants
were collected for the determination of cisplatin. After sampling
our supernatants, the incubation medium was replaced by fresh
PBS and the tubes were placed back in the incubator. The
cisplatin content of these solutions was determined by measuring
the absorbance at 310 nm with a non-gradient mobile phase
consisting of 0.9% NaCl and methanol (v/v, 25/75) at a constant
flow rate of 1.0 mL/min.
In vitro cytotoxicity study
The MTT assay was used to evaluate the toxicity of blank
nanoparticles,cisplatin-loadednanoparticlesandfreecisplatinagainst
IGROV1-CP ovarian cancer cells [25]. The cells were seeded into
plastic 96-well plates at 3610
3 cells per well. Twenty-four hours after
plating, cisplatin, blank nanoparticles and cisplatin-loaded nanopar-
ticles (both suspended in culture medium) at various concentrations
were added to the wells. A total of 50 mL of MTT solution (5 mg/mL
in PBS, pH 7.4) was added into each well and incubated at 37uCf o r
3 hours. The solution was withdrawn, and then 200 mLo fa c i d i f i e d
isopropanol (0.33 mL HCl in 100 mL isopropanol) was added and
agitated thoroughly to dissolve the formazan crystals. The solution
was immediately read on a microplate reader (TECAN INFINIT
M200, USA) at a wavelength of 490 nm. The experiments were
performed independently three times. Cytotoxicity was expressed as
inhibition percentage of cell viability.
In vivo evaluation of acute toxicity
ICR mice were used to assess relative toxicity after intravenous
administration of cisplatin-loaded nanoparticles. All mice were
raised under specific pathogen-free (SPF) environments. All animal
experiments were performed in full compliance with guidelines
approved by the Animal Care Committee of Zhejiang Chinese
Medical University. In order to determine median lethal dose
(LD50), the mice were administered with 0.8 mL of cisplatin-
loaded nanoparticles in saline solution at the doses of 40, 60, 80,
100 and 120 mg/kg through intravenous injection. Each group
was 10 mice. The survival time of each animal was recorded up to
14 days and LD50 was calculated according to the Bliss
mathematical scheme.
HE staining
After treatment with five consecutive different formulations,
BALB/c mice were sacrificed by overdose of ether inhalation
anesthesia. Macroscopic examination and histological analysis of
heart, lung, liver, spleen and kidney tissues were performed. The
organs were firstly fixed in 10% neutral-buffered formalin solution,
and then embedded in paraffin. Embedded sections were cut at
5 mm and stained with hematoxylin and eosin (HE). The images
were acquired at 4006magnification. Detail histopathological and
morphological changes were reviewed by a pathologist at Zhejiang
University of Traditional Chinese Medicine.
In situ cell death detection of ovarian cancer xenografts
The tumors in cisplatin-loaded nanoparticles (3 mg/kg once per
4 days) treated mice were sequentially excised, formalin-fixed and
paraffin-embedded. Embedded tissue samples were examined by
TUNEL assay as described previously [25]. Briefly, tissue sections
were dewaxed and rehydrated according to standard protocols
(e.g., by heating at 60uC followed by washing in xylene and
rehydration through a graded series of ethanol and double distilled
water). After two more washes in PBS, the slides were incubated
with proteinase K solution for 30 minutes at room temperature.
After rinsing slide(s) twice with PBS, reaction mixture (consisting of
Enzyme Solution and Label Solution) in the TUNEL detection kit
was then added and incubated at 37uC in the dark for 1 hour.
Slides were rinsed with PBS for 3 times, and the samples were
directly analyzed under an OLYMPUS IX-71 microscope. An
excitation wavelength in the range of 488 nm and emission
wavelength in the range of 520 nm (green) was used. Apoptotic
cells were photographed with microscope.
In vivo antitumor efficacy
The antitumor efficacy of cisplatin-loaded nanoparticles was
evaluated by using BALB/c female mice bearing IGROV1-CP
cells. Cell suspension (7610
6 per mice) was prepared and
inoculated into the subcutaneous dorsa of mice. Nearly two weeks
after inoculation (when mean tumor volume was approximately
100–130 mm
3), tumor-bearing mice (eight mice per group) were
injected with saline, blank nanoparticles, free cisplatin and
cisplatin-loaded nanoparticles via the lateral tail vein. The
administrations were given once every 4 days at the cisplatin dose
of 3 mg/kg. The treatment period was 3 weeks. The tumor
volume was calculated by using a6b
2/2, where a is the largest
diameter and b is the smallest diameter. In addition, the toxicities
of free cisplatin and cisplatin-loaded nanoparticles were evaluated
by monitoring the changes in body weight and survival rates.
Statistical analysis
The difference in tumor volume, survival rate and tumor weight
between the treatment and control groups was assessed by analysis
of variance. The data were normally distributed. All data were
presented as Mean 6 SD. All statistical analysis was carried out by
SPSS Version 11.0 software. A significant difference was
considered at p,0.05.
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